Metastasectomy in patients with renal cell carcinoma: when and how?
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
18
12
2020
Statut:
ppublish
Résumé
The role of metastasectomy in the management of metastatic renal cell carcinoma (mRCC) remains controversial. The aim of this review is to summarize and evaluate the recent findings about the surgical treatment of patients with mRCC focusing on the literature published in the last 2 years. Despite the lack of randomized controlled trials, the benefit of metastasectomy in term of cancer-specific and overall survival have been demonstrated in large observational studies. Results of ongoing clinical trials evaluating the impact of combination of surgical and systemic therapies are eagerly awaited and may shed the light on a new treatment armamentarium in this subset of patients. Several novel systemic agents have emerged and is continuously changing the treatment paradigm in patients with advanced RCC. However, surgical resection of the primary tumor and metastatic deposits represents a definitive cure option in well selected patients.
Identifiants
pubmed: 32464043
doi: 10.1097/MOU.0000000000000768
pii: 00042307-202007000-00020
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
602-609Références
Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treatment Opt Oncol 2003; 4:385–390.
Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012; 23:973–980.
Milovic N, Lazic M, Aleksic P, et al. Rare locations of metastastatic renal cell carcinoma: a presentation of three cases. Vojnosanitetski pregled 2013; 70:881–886.
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med 2013; 369:722–731.
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Engl J Med 2015; 373:1814–1823.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 2015; 373:1803–1813.
Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. New Engl J Med 2016; 375:2246–2254.
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. New Engl J Med 2017; 376:354–366.
European Association U. European Association of Urology Guidelines. European Association of Urology Guidelines Office, 2018 Edition.Arnhem, The Netherlands: 2018.
Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014; 15:e549–e561.
Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol 2017; 197:44–49.
Appleman LJ, Maranchie JK. Systemic therapy following metastasectomy for renal cell carcinoma: using insights from other clinical settings to address unanswered questions. Urologic oncology 2018; 36:17–22.
Li JR, Ou YC, Yang CK, et al. The impact of local intervention combined with targeted therapy on metastatic renal cell carcinoma. Anticancer Res 2018; 38:5339–5345.
Rausch S, Gouttefangeas C, Hennenlotter J, et al. Results of a phase 1/2 study in metastatic renal cell carcinoma patients treated with a patient-specific adjuvant multipeptide vaccine after resection of metastases. Eur Urol Focus 2017; 5:604–607.
Barney JD, Churchill Edward J. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. Read at the annual meeting of the American Association of Genito-Urinary Surgeons, Absecon, New Jersey, May 2. J Urol 1939; 42:269–276.
Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996–1003.
Ohtaki Y, Shimizu K, Aokage K, et al. Histology is a prognostic indicator after pulmonary metastasectomy from renal cell carcinoma. World J Surg 2017; 41:771–779.
Zhao Y, Li J, Li C, et al. Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 2017; 41:70–77.
Meyer C, Bartsch D, Mirow N, Kirschbaum A. Video-assisted laser resection of lung metastases-feasibility of a new surgical technique. Thorac Cardiovasc Surg 2017; 65:382–386.
Meacci E, Nachira D, Congedo MT, et al. Lung metastasectomy following kidney tumors: outcomes and prognostic factors from a single-center experience. J Thorac Dis 2017; 9: (Suppl 12): S1267–S1272.
Thomas AZ, Adibi M, Borregales LD, et al. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol 2015; 25:381–389.
Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89:1794–1801.
Higuchi T, Yamamoto N, Hayashi K, et al. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint J 2018; 100-B:1241–1248.
Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966–970.
Higuchi T, Yamamoto N, Hayashi K, et al. The efficacy of wide resection for musculoskeletal metastatic lesions of renal cell carcinoma. Anticancer Res 2018; 38:577–582.
Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55:28–34.
Nagaraja H, Srivatsa N, Hemalatha S, et al. Role of RPLND and metastasectomy in the management of oligometastatic renal cell carcinoma. Indian J Surg Oncol 2018; 9:105–109.
Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011; 185:1615–1620.
Delacroix SE Jr, Chapin BF, Chen JJ, et al. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol 2011; 186:1236–1241.
Jakubowski CD, Vertosick EA, Untch BR, et al. Complete metastasectomy for renal cell carcinoma: comparison of five solid organ sites. J Surg Oncol 2016; 114:375–379.
Staehler MD, Kruse J, Haseke N, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 2010; 28:543–547.
Ruys AT, Tanis PJ, Nagtegaal ID, et al. Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 2011; 18:1932–1938.
Thelen A, Jonas S, Benckert C, et al. Liver resection for metastases from renal cell carcinoma. World J Surg 2007; 31:802–807.
Fokas E, Henzel M, Hamm K, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients. Strahlenther Onkol 2010; 186:210–217.
Ikushima H, Tokuuye K, Sumi M, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 48:1389–1393.
Lee SR, Gemenetzis G, Cooper M, et al. Long-term outcomes of 98 surgically resected metastatic tumors in the pancreas. Ann Surg Oncol 2017; 24:801–807.
Tanis PJ, van der Gaag NA, Busch OR, et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 2009; 96:579–592.
Benhaim R, Oussoultzoglou E, Saeedi Y, et al. Pancreatic metastasis from clear cell renal cell carcinoma: outcome of an aggressive approach. Urology 2015; 85:135–140.
Grassi P, Doucet L, Giglione P, et al. Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis. PLoS One 2016; 11:e0151662–e151670.
Verbiest A, Couchy G, Job S, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy. Eur Urol 2018; 74:474–480.
Meyer CP, Sun M, Karam JA, et al. Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol 2017; 72:171–174.
Joyce DD, Psutka SP, Groeschl RT, et al. Complications and outcomes associated with surgical management of renal cell carcinoma involving the liver: a matched cohort study. Urology 2017; 99:155–161.
Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996; 34:251–266.
Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 2017; 14:549–563.
Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 1985; 11:2007–2009.
Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 2014; 88:254–262.
Wang CJ, Christie A, Lin MH, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 2017; 98:91–100.
Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 2015; 54:148–157.
Franzese C, Franceschini D, Di Brina L, et al. Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 2019; 201:70–75.
Stenman M, Sinclair G, Paavola P, et al. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014. Radiother Oncol 2018; 127:501–506.
Zeng J, Baik C, Bhatia S, et al. Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol 2014; 15:e426–e434.
Miller JA, Balagamwala EH, Angelov L, et al. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. J Neurosurg Spine 2016; 25:766–774.
Staehler M, Haseke N, Nuhn P, et al. Simultaneous antiangiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 2011; 108:673–678.
Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo, Brazil) 2018; 73: (Suppl 1): e557s.